Literature DB >> 10076130

Risk factors for rapid-onset cervical cancer.

A Hildesheim1, O Hadjimichael, P E Schwartz, C M Wheeler, W Barnes, D M Lowell, J Willett, M Schiffman.   

Abstract

OBJECTIVES: The current study was designed to elucidate risk factors associated with the development of cervical cancer during the course of routine Papanicolaou smear screening (rapid-onset cervical cancer). STUDY
DESIGN: Four hundred eighty-three women diagnosed with invasive cervical cancer, representing 73% of all such tumors diagnosed in Connecticut between 1985 and 1990, were studied. Papanicolaou smear screening and risk factor information was obtained by questionnaire and physician record review. Results from human papillomavirus deoxyribonucleic acid testing by polymerase chain reaction of tumor samples were available for 278 study participants. Prediagnostic Papanicolaou smear slides were reviewed for 67% of cases with a screening history. Screening history information, slide review, and questionnaire data were used to classify women as having rapid-onset cervical cancer (n = 43), possible rapid-onset cervical cancer (n = 111), or normal-onset cervical cancer (n = 329).
RESULTS: Compared with normal-onset cases, rapid-onset cases tended to be younger (P =.001) and were more likely to be white (P =.002), diagnosed with adenocarcinomas or adenosquamous carcinomas (P =.001), and diagnosed with early-stage disease (P =.001). Cases diagnosed as possible rapid-onset disease tended to have a profile that was intermediate to that observed for rapid-onset and normal-onset cases. Human papillomavirus deoxyribonucleic acid was detected in 75.2% of cases tested. Compared with women who tested positive for human papillomavirus type 16 or other, those positive for human papillomavirus type 18 had a relative risk for rapid-onset disease of 1.6 (95% confidence interval 0.52-4.9). No significant association was observed between type 18 and possible rapid-onset disease when possible rapid-onset cases were compared with women diagnosed with normal-onset cervical cancer (relative risk 0.67, 95% confidence interval 0.29-1.6). Oral contraceptive use, cigarette smoking, number of pregnancies, and a maternal history of cervical cancer were not significantly associated with rapid-onset disease.
CONCLUSIONS: Results from this study suggest that the risk factors associated with the development of rapid-onset cervical cancer are similar to those for normal-onset disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10076130     DOI: 10.1016/s0002-9378(99)70256-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

1.  A Suggested Approach to Simplify and Improve Cervical Screening in the United States.

Authors:  Mark Schiffman; Nicolas Wentzensen
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

Review 2.  Human papillomavirus vaccine and cervical cancer prevention.

Authors:  Ana Oaknin; Ma Pilar Barretina
Journal:  Clin Transl Oncol       Date:  2008-12       Impact factor: 3.405

3.  Experiences of Cervical Cancer Survivors in Rural Eastern North Carolina: a Qualitative Assessment.

Authors:  Alice R Richman; Jamie L Troutman; Essie Torres
Journal:  J Cancer Educ       Date:  2016-06       Impact factor: 2.037

4.  Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.

Authors:  Somayeh Pouyanfard; Gloria Spagnoli; Lorenzo Bulli; Kathrin Balz; Fan Yang; Caroline Odenwald; Hanna Seitz; Filipe C Mariz; Angelo Bolchi; Simone Ottonello; Martin Müller
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

5.  Cervical carcinoma rates among young females in the United States.

Authors:  Vicki B Benard; Meg Watson; Philip E Castle; Mona Saraiya
Journal:  Obstet Gynecol       Date:  2012-11       Impact factor: 7.661

6.  Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques.

Authors:  Jian Yan; Kristina Harris; Amir S Khan; Ruxandra Draghia-Akli; Duane Sewell; David B Weiner
Journal:  Vaccine       Date:  2008-04-14       Impact factor: 3.641

Review 7.  [What does HPV vaccination mean for gynecologic cancer screening?].

Authors:  K U Petry
Journal:  Hautarzt       Date:  2007-06       Impact factor: 0.751

8.  Evaluation of candidate methylation markers to detect cervical neoplasia.

Authors:  Narayan Shivapurkar; Mark E Sherman; Victor Stastny; Chinyere Echebiri; Janet S Rader; Ritu Nayar; Thomas A Bonfiglio; Adi F Gazdar; Sophia S Wang
Journal:  Gynecol Oncol       Date:  2007-09-25       Impact factor: 5.482

9.  Age of diagnosis of squamous cell cervical carcinoma and early sexual experience.

Authors:  Zoe R Edelstein; Margaret M Madeleine; James P Hughes; Lisa G Johnson; Stephen M Schwartz; Denise A Galloway; Joseph J Carter; Laura A Koutsky
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-24       Impact factor: 4.254

10.  Screening adolescents and young women.

Authors:  Lori A Boardman; Katina Robison
Journal:  Obstet Gynecol Clin North Am       Date:  2013-04-17       Impact factor: 2.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.